The researchers conducted the first randomized, placebo-controlled, double-blind study of gastric acid suppression among patients with laryngitis in the United States.
They reported their findings in the American Journal of Gastroenterology.
Patients diagnosed with idiopathic chronic laryngitis were randomized to receive either lansoprazole 30 mg orally, twice a day, or a matching placebo for 3 months.
Before randomization, all patients underwent upper endoscopy, dual probe ambulatory 24 hour esophageal pH-metry, and laryngoscopy. They also completed a symptom questionnaire for gastro-esophageal reflux disease (GERD) and laryngitis.
|Patients with complete symptomatic response: |
|American Journal of Gastroenterology|
The primary outcome of treatment was the complete resolution of laryngeal symptoms.
A total of 22 patients with symptoms and signs of chronic laryngitis were enrolled, 20 of whom completed the study.
At baseline, there were no significant differences between the two groups with regards to GERD symptoms, erosive esophagitis, proximal and distal esophageal pH-metry, or laryngeal signs and symptoms.
In an intention-to-treat analysis, six patients in the lansoprazole group (50%) and only one patient (10%) in the placebo group were found to achieve a complete symptomatic response.
Apart from receiving lansoprazole, there were no significant differences between responders and non-responders in any of baseline esophageal or laryngeal signs and symptoms.
Researcher H. B. El-Serag, of the Houston VA Medical Center and Baylor College of Medicine, said on behalf of the group, "Empirical treatment with lansoprazole is efficacious in relieving symptoms of laryngitis compared with placebo.
"Such treatment can be considered as a first-line option in managing patients with idiopathic chronic laryngitis."